Download PDF
Thromb Haemost 2008; 99(05): 970-972
DOI: 10.1160/TH07-12-0742
Letters to the Editor
Schattauer GmbH

No clear link between VKORC1 genetic polymorphism and the risk of venous thrombosis or peripheral arterial disease

David M. Smadja
1   Université Paris Descartes, Paris, France
3   INSERM Unité 765, Faculté de Pharmacie, Paris, France
,
Marie-Anne Loriot
1   Université Paris Descartes, Paris, France
2   AP-HP, Hôpital européen Georges Pompidou, Paris, France
4   INSERM Unité 775, Paris, France
,
Lucia A. Hindorff
5   Department of Epidemiology, School of Public Health, University of Washington, Seattle, Washington, USA
,
Lucille Mellottee
1   Université Paris Descartes, Paris, France
4   INSERM Unité 775, Paris, France
,
Pascale Gaussem
1   Université Paris Descartes, Paris, France
2   AP-HP, Hôpital européen Georges Pompidou, Paris, France
3   INSERM Unité 765, Faculté de Pharmacie, Paris, France
,
Joseph Emmerich
1   Université Paris Descartes, Paris, France
2   AP-HP, Hôpital européen Georges Pompidou, Paris, France
3   INSERM Unité 765, Faculté de Pharmacie, Paris, France
› Author Affiliations
Further Information

Publication History

Received 17 December 2007

Accepted after minor revision 14 March 2008

Publication Date:
30 November 2017 (online)

    Permissions and Reprints

 

 

  • References

  • 1 Cranenburg EC, Schurgers LJ, Vermeer C. Vitamin K: the coagulation vitamin that became omnipotent. Thromb Haemost 2007; 98: 120-125.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 2 Luo G, Ducy P, McKee MD. et al. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature 1997; 386: 78-81.
    CrossrefPubMedGoogle Scholar
  • 3 Herrmann SM, Whatling C, Brand E. et al. Polymorphisms of the human matrix gla protein (MGP) gene, vascular calcification, and myocardial infarction. Arterioscler Thromb Vasc Biol 2000; 20: 2386-2393.
    CrossrefPubMedGoogle Scholar
  • 4 Wang Y, Zhen Y, Shi Y. et al. Vitamin k epoxide reductase: a protein involved in angiogenesis. Mol Cancer Res 2005; 3: 317-323.
    CrossrefPubMedGoogle Scholar
  • 5 Rost S, Fregin A, Ivaskevicius V. et al. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 2004; 427: 537-541.
    CrossrefPubMedGoogle Scholar
  • 6 Bodin L, Horellou MH, Flaujac C. et al. A vitamin K epoxide reductase complex subunit-1 (VKORC1) mutation in a patient with vitamin K antagonist resistance. J Thromb Haemost 2005; 3: 1533-1535.
    CrossrefPubMedGoogle Scholar
  • 7 Rieder MJ, Reiner AP, Gage BF. et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005; 352: 2285-2293.
    CrossrefPubMedGoogle Scholar
  • 8 Geisen C, Watzka M, Sittinger K. et al. VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation. Thromb Haemost 2005; 94: 773-779.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 9 Bodin L, Verstuyft C, Tregouet DA. et al. Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. Blood 2005; 106: 135-140.
    CrossrefPubMedGoogle Scholar
  • 10 Oldenburg J, Bevans CG, Fregin A. et al. Current pharmacogenetic developments in oral anticoagulation therapy: the influence of variant VKORC1 and CYP2C9 alleles. Thromb Haemost 2007; 98: 570-578.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 11 Siguret V. Impact of pharmacogenetics on interindividual variability in the response to vitamin K antagonist therapy. Pathol Biol (Paris) 2007; 55: 295-298.
    CrossrefPubMedGoogle Scholar
  • 12 Loriot MA, Beaune P. Vitamin K epoxide reductase: Fresh blood for oral anticoagulant therapies. Rev Med Interne 2006; 27: 979-982.
    CrossrefPubMedGoogle Scholar
  • 13 Wang Y, Zhang W, Zhang Y. et al. VKORC1 haplotypes are associated with arterial vascular diseases (stroke, coronary heart disease, and aortic dissection). Circulation 2006; 113: 1615-1621.
    CrossrefPubMedGoogle Scholar
  • 14 Lacut K, Larramendy-Gozalo C, Le Gal G. et al. Vitamin K epoxide reductase genetic polymorphism is associated with venous thromboembolism: results from the EDITH Study. J Thromb Haemost 2007; 5: 2020-2024.
    CrossrefPubMedGoogle Scholar
  • 15 Watzka M, Nebel A, El Mokhtari NE. et al. Functional promoter polymorphism in the VKORC1 gene is no major genetic determinant for coronary heart disease in Northern Germans. Thromb Haemost 2007; 97: 998-1002.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 16 Hindorff LA, Heckbert SR, Smith N. et al. Common VKORC1 variants are not associated with arterial or venous thrombosis. J Thromb Haemost 2007; 5: 2025-2027.
    CrossrefPubMedGoogle Scholar
  • 17 Reny JL, Alhenc-Gelas M, Fontana P. et al. The factor II G20210A gene polymorphism, but not factor V Arg506Gln, is associated with peripheral arterial disease: results of a case-control study. J Thromb Haemost 2004; 2: 1334-1340.
    CrossrefPubMedGoogle Scholar
  • 18 Fontana P, Gaussem P, Aiach M. et al. P2Y12 H2 haplotype is associated with peripheral arterial disease: a case-control study. Circulation 2003; 108: 2971-2973.
    CrossrefPubMedGoogle Scholar